Emcure Pharmaceuticals share price today slipped 5.71% on Bombay Stock Exchange to Rs 974.30 per share. The company said its European subsidiary Tillomed Laboratories Limited acquired strategic pharma portfolio from Manx for £ 19.7 million. The company has a market capitalisation of Rs 18,399.78 crore. Its return on equity stood at 6.28%. In last 1-week, Emcure Pharmaceuticals shares slipped 9.18%. It is worth mentioning that FII/FPI’s holdings zoomed from 2.91% to 3.05% for December 2024 quarter. Check more details below:
Emcure Pharmaceuticals’s Subsidiary Acquires Pharma Portfolio From Manx
According to the exchange filing of Emcure Pharmaceuticals dated April 4, 2025, “Tillomed Laboratories Limited, a subsidiary of Emcure Pharmaceuticals Ltd, has entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited (collectively Manx).
Under the APA, Tillomed will acquire Manx’s product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property (collectively Intellectual Properties) and the relevant stocks for around £ 19.7 mn (including £ 4.7mn for inventory) of which £ 6.2 mn will be upfront and rest as milestone payments over the next 18 months. The deal marks a strategic milestone for Tillomed and will strengthen the company’s product offerings, expand its market reach, and enhance its ability to meet the evolving needs of patients, added the exchange filing.
Speaking on the latest development, Ajit Srimal, CEO Tillomed said, “Through the acquisition of Manx’s established and high-quality products portfolio, we reinforce our commitment to delivering accessible healthcare solutions. The acquired assets will help diversify our portfolio and strengthen our market presence.”
Emcure Pharmaceuticals Shares Performance
The 52-week high of Emcure Pharmaceuticals share price stood at Rs 1,577.50 per share (as on 18/09/2024) and 52-week low price is Rs 911.75 per share (as on 17/03/2025), respectively. The pharmaceuticals company’s shares slipped sharply by 33.33% year-to-date and fell again by 31.62% in Last 6-months.
Why Emcure Pharmaceuticals Shares Declined Today?
The stock witnessed steep fall of 5.71% to Rs 974.30 per share. The decline in the shares of the company came after reports surfaced that US President Donald Trump is planning for possible tariff on pharmaceuticals goods.
Emcure Pharmaceuticals Financials
The company announced its net profit for December 2024 quarter at Rs 50.20 crore from Rs 86.92 crore recorded in September 2024 quarter. The EPS of the stock plunged to Rs 2.65 for December 2024 from Rs 4.62 reported in September 2024 quarter. The company’s revenue was reported at Rs 1028.81 crore for the quarter under review as against Rs 1104.63 crore declared in September 2024.
Emcure Pharmaceuticals Dividend History
The company never recommended any dividend so far. It has not declared any bonus share as well.
Disclaimer: The story highlights acquisition update and should not be considered as investment advice by the Moneydaily.in or the Author. Moneydaily.in and the author will not be held responsible for any losses caused as a result of decisions based on the above information. Moneydaily.in advises readers to do their own research or consult a SEBI registered investment advisor before making any investment decisions.
Recommended: Mazagon Dock OFS: Govt Set To Offload 4.83% Stake, Dividend Next Week
Leave a Reply